



Use of sorafenib (Nexavar®) for advanced renal cell carcinoma within NHS Wales

**AWMSG ADVICE SUPERSEDED BY
NICE GUIDANCE (TA178)**

NICE GUIDANCE ISSUED AUGUST 2009

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Dear Colleague

The Minister for Health & Social Services has endorsed AWMSG's recommendation that the use of sorafenib (Nexavar®) is not supported for use within NHS Wales.

AWMSG recommendation:

AWMSG recommends that sorafenib (Nexavar®) should not be made available for use within NHS Wales for the treatment of advanced renal cell carcinoma in patients who have failed prior interferon- α or interleukin-2 based therapy, or are considered unsuitable for such therapy, on the grounds of lack of evidence of cost-effectiveness.

The appraisal meeting documentation is available to view on the [AWMSG website](#).

This information has been disseminated by the AWMSG Secretariat (WMP).

Please note that guidance subsequently issued by the National Institute for Health & Clinical Excellence (NICE) will supersede that of AWMSG.

Professor Philip A. Routledge
Acting AWMSG Chairman

5th June 2007